The metabolism of Zilbrysq (tildipiritide) has not been extensively detailed in publicly available information, suggesting a limited focus on its metabolic pathways in current research or regulatory submissions. Information regarding the specific enzymes involved in its breakdown or the primary routes of excretion is not readily found.
How is Zilbrysq absorbed and distributed in the body?
Details on the absorption and distribution of Zilbrysq within the body are not extensively documented in the provided information. The mechanisms and extent to which the drug enters the bloodstream and reaches target tissues are not specified.
What is Zilbrysq used to treat?
Zilbrysq is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) [1]. This includes individuals experiencing clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
How does Zilbrysq work?
Zilbrysq is a sphingosine-1-phosphate (S1P) receptor modulator [1]. By selectively binding to S1P receptors on lymphocytes, it traps these immune cells in lymph nodes, reducing their migration to the central nervous system and thereby mitigating inflammatory autoimmune attacks on myelin sheaths in MS [1].
What are the potential side effects of Zilbrysq?
Common side effects associated with Zilbrysq use include nasopharyngitis, upper respiratory tract infection, headache, and hypertension [1]. More serious potential adverse events involve liver enzyme elevations, bradycardia (slow heart rate), macular edema, and increased risk of infections [1]. Patients may also experience effects on pulmonary function and fetal harm if used during pregnancy [1].
What is the patent and exclusivity status for Zilbrysq?
Information regarding the specific patent and exclusivity status for Zilbrysq, including its patent expiry dates, is not provided. DrugPatentWatch.com is a resource that tracks patent information for pharmaceutical products [2].
Who manufactures Zilbrysq?
Zilbrysq is manufactured by Bristol Myers Squibb [1].